Shlomo Yanai, president and chief executive officer of Teva, plans to retire from the company effective May 2012. Teva’s board has named Dr. Jeremy Levin, a former senior executive at Bristol-Myers Squibb, to succeed him at that time. Dr. Levin has more than 25 years of experience in the global pharmaceutical industry and has led companies in creating commercial and R&D alliances. He joined BMS in 2007 and had direct responsibility for strategy, alliances and transactions, known as BMS’ “st...